Table 2.
Cervical screening methods result from histology outcome of ASCUS and CIN+.
| Cervical screening methods and results | Result category | Categories of histological analysis (N = 78) | Positive (ASCUS, CIN+) | Negative | Total | p value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ASCUS | CIN1 | CIN2 | CIN3 | ICC | ||||||
| Primary screening approach | ||||||||||
| Positive VIA test | ||||||||||
| Normal | FP | 24 (7.6) | 2 (0.6) | 26 (8.2) | 194 (61.2) | 220 (69.4) | 0.001∗ | |||
| Abnormal | TP | 10 (3.2) | 15 (4.7) | 16 (5.0) | 6 (1.9) | 5 (1.6) | 52 (16.4) | 45 (14.2) | 97 (30.6) | |
| Positive HPV DNA-PCR | ||||||||||
| Negative | FP | 23 (7.3) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 26 (8.2) | 207 (65.3) | 233 (73.5) | 0.001∗ | |
| Positive | TP | 11 (3.5) | 17 (5.4) | 15 (4.7) | 5 (1.6) | 4 (1.3) | 52 (16.4) | 32 (10.1) | 84 (26.5) | |
| Positive Pap smear test | ||||||||||
| Normal | FP | 22 (6.9) | 2 (0.6) | 3 (0.9) | 1 (0.3) | 28 (8.8) | 208 (65.6) | 236 (74.4) | 0.001∗ | |
| Abnormal | TP | 12 (3.8) | 15 (4.7) | 13 (4.1) | 5 (1.6) | 5 (1.6) | 50 (15.8) | 31 (9.8) | 81 (25.6) | |
| Triage screening approach with positive primary test | ||||||||||
| Positive VIA test | ||||||||||
| Pap smear | ||||||||||
| Normal | FP | 3 (0.9) | 1 (0.3) | 4 (1.3) | 11 (3.5) | 3 (0.9) | 0.001∗ | |||
| Abnormal | TP | 9 (2.8) | 14 (4.4) | 13 (4.1) | 5 (1.6) | 5 (1.6) | 46 (14.5) | 20 (6.3) | 46 (14.5) | |
| Total | 12 (3.8) | 15 (4.7) | 13 (4.1) | 5 (1.6) | 5 (1.6) | 50(15.8) | 31 (9.8) | 50 (15.8) | ||
| Positive HPV DNA-PCR | ||||||||||
| VIA test | ||||||||||
| Normal | FP | 2 (0.6) | 2 (0.6) | 3 (0.9) | 1 (0.3) | 8 (2.5) | 13 (4.1) | 21 (6.6) | 0.001∗ | |
| Positive | TP | 7 (2.2) | 14 (4.4) | 12 (3.8) | 5 (1.6) | 5 (1.6) | 43 (13.6) | 20 (6.3) | 63 (19.9) | |
| Total | 9 (2.8) | 16 (5.0) | 15 (4.7) | 6 (1.9) | 5 (1.6) | 51 (16.1) | 33 (10.4) | 84 (26.5) | ||
| Abnormal Pap smear | ||||||||||
| DNA-PCR | ||||||||||
| Negative | FP | 3 (0.9) | 1 (0.3) | 1 (0.3) | 5 (1.6) | 21 (6.6) | 3 (0.9) | 0.001∗ | ||
| Positive | TP | 7 (2.2) | 14 (4.4) | 15 (4.7) | 6 (1.9) | 5 (1.6) | 47 (14.8) | 24 (7.6) | 47 (14.8) | |
| Total | 10 (3.2) | 15 (4.7) | 16 (5.0) | 6 (1.9) | 5 (1.6) | 52 (16.4) | 45 (14.2) | 52 (16.4) | ||
| Total | 34 (10.7) | 17 (5.3) | 16 (5.0) | 6 (1.9) | 5 (1.6) | 78 (24.6) | 239 (75.4) | 317 (100.0) | 0.001∗ | |
VIA test: visual inspection with acetic acid test; HPV DNA-PCR: human papillomavirus deoxyribonucleic polymerase chain reaction; Abnormal histology: ASCUS: atypical squamous cells of unknown significant; CIN2+: cervical intraepithelial neoplasia; and ICC: intraepithelial cervical carcinoma; ∗: the probability at the 0.001 level; FP: false positive; TP: true positive. Table 2 shows the Primary cervical screening approach where results obtained by VIA, HPV-PCR, and Pap smear are categorized as positive, negative, normal, or abnormal by histology reports of ASCUS and CIN+ including ICC. In the triage screening approach, positive primary test results are combined with triage test results and categorized by histology report. Total positive results of ACSUS, CIN1, 2,3, and ICC are also shown alongside negative samples and total (N = 317).